NEWS

Press Releases AND Media
Press Releases

Attralus to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference

Source Author:

November 22, 2021
PDF Version
Note: Source article is behind a pay wall
Note: Source article is only available to members, but subscription is free

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, is pleased to announce the company’s participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021. A presentation by Attralus will be available for registered attendees via the Piper Sandler conference site from November 22 to December 2.

About Attralus

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and the company is headquartered in South San Francisco.

Contact

Luke Heagle
Real Chemistry
(910) 619-5764
lheagle@realchemistry.com


SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 -- Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, is pleased to announce the company’s participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 29 – December 2, 2021. A presentation by Attralus will be available for registered attendees via the Piper Sandler conference site from November 22 to December 2.

About Attralus

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. The company’s proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis. Attralus was founded by scientific experts in the field of amyloidosis and the company is headquartered in South San Francisco.

Contact

Luke Heagle
Real Chemistry
(910) 619-5764
lheagle@realchemistry.com


<< Back to All News

our apologies

TABLET & MOBILE EXPERIENCES
ARE STILL UNDER CONSTRUCTION

Please view on a desktop or laptop computer.